Easterly Investment Partners LLC Sells 16,281 Shares of Collegium Pharmaceutical, Inc. $COLL

Easterly Investment Partners LLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 31.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 35,131 shares of the specialty pharmaceutical company’s stock after selling 16,281 shares during the quarter. Easterly Investment Partners LLC’s holdings in Collegium Pharmaceutical were worth $1,627,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Versor Investments LP bought a new stake in Collegium Pharmaceutical during the 3rd quarter valued at approximately $1,337,000. Ballast Asset Management LP boosted its stake in Collegium Pharmaceutical by 31.1% during the 3rd quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company’s stock valued at $4,000,000 after purchasing an additional 27,109 shares during the period. Wedge Capital Management L L P NC bought a new stake in Collegium Pharmaceutical during the 4th quarter valued at approximately $2,697,000. JPMorgan Chase & Co. boosted its stake in Collegium Pharmaceutical by 193.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock valued at $7,409,000 after purchasing an additional 139,689 shares during the period. Finally, Hillsdale Investment Management Inc. boosted its stake in Collegium Pharmaceutical by 14.1% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 203,000 shares of the specialty pharmaceutical company’s stock valued at $7,103,000 after purchasing an additional 25,100 shares during the period.

Insider Activity

In other news, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $31.78 on Tuesday. The stock has a 50 day moving average of $34.03 and a two-hundred day moving average of $41.28. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical, Inc. has a 12 month low of $28.74 and a 12 month high of $50.79. The company has a market capitalization of $1.03 billion, a P/E ratio of 15.58 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter last year, the company earned $1.49 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a research note on Tuesday, February 10th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.